Rheumatology

Question 1

etanercept (Enbrel)

Answer 1

Anti-TNF
soluble receptor
Toxicity: infection (especially TB re-activation), demyelination disease, induction of autoimmunity, exacerbation of CHF, possible malignancy (skin CA)

Question 2

inflixamab (remicade)

Answer 2

Anti-TNF
Chimeric antibody
Toxicity: infection (especially TB activation), demylenating disease, induction of autoimmunity, exacerbation of CHF, possible skin malignancy

Question 3

Adalimumab (Humira)

Answer 3

Anti-TNF
Human monoclonal antibody
Toxicity: infection (especially TB reactivation), demyelination disease, induction of autoimmunity, exacerbation of CHF, skin malignancy

Question 4

Abatacept (Orencia)

Answer 4

Co-stimulation modulators
MOA: Prevent T-cell activation by interfering with antigen presenting call interaction with T-cells
Toxicity: infection, exascerbation of COPD

Question 5

Rituximab

Answer 5

MOA: depletes B cells
Toxicity: infection, death, central nervous system (possible progressive multifocal leukoencephalopathy)

Question 6

Anakinra (Kineret)

Answer 6

IL-1 receptor antagonist. Antagonizes IL-1 by binding to the IL-1 receptor
Toxicity: injection site reactions, infection

Question 7

Tocilizumab (Actemra)

Answer 7

IL-6 antagonist
MOA: antagonizes IL-6 by binding to IL-6 receptor
Toxicity: Transaminase elevation, leucopenia, thrombpcytopenia, yperlypidemia, bowel perforation, infetion

Question 8

Tofacitinib (Xeljanz)

Answer 8

MOA: Inhibits intracellular protein kinases (Janus KInase {JAK])
Toxicity: Leukpenia, anemia, transaminase elevation, hyperlipidemia, bowel performation, infection